Form 8-K - Current report:
SEC Accession No. 0001193125-25-115978
Filing Date
2025-05-08
Accepted
2025-05-08 16:15:59
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d904349d8k.htm   iXBRL 8-K 25698
2 EX-99.1 d904349dex991.htm EX-99.1 39134
6 GRAPHIC g904349g0507205736235.jpg GRAPHIC 3298
  Complete submission text file 0001193125-25-115978.txt   202465

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20250508.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20250508_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20250508_pre.xml EX-101.PRE 11264
17 EXTRACTED XBRL INSTANCE DOCUMENT d904349d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 25926354
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)